U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07714369) titled 'Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache' on July 14.
Brief Summary: The purpose of this study is to assess headache response rate for minimal pain at 30 minutes following zavegepant administration and to assess additional effectiveness and treatment failure endpoints at various timepoints after zavegepant administration
Study Start Date: Oct. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Cluster Headache
Intervention:
DRUG: Zavegepant 20 mg
Participants will administer zavegepant 10 mg twice in quick succession (once into the left nostril, once into the right nostril, for a total of 2...